FDA approves ACADIA Pharmaceuticals' NUPLAZIDTM (pimavanserin)
ACADIA Pharmaceuticals announced the FDA has approved NUPLAZID (pimavanserin) for treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. In 2014, the FDA designated NUPLAZID as a Breakthrough Therapy for this condition. April 29, 2016